# Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension

> **NCT02480764** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 612 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Azilsartan medoxomil
- **DRUG:** Valsartan
- **DRUG:** Azilsartan medoxomil Placebo
- **DRUG:** Valsartan Placebo

## Key facts

- **NCT ID:** NCT02480764
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-27
- **Primary completion:** 2017-09-22
- **Final completion:** 2017-10-13
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02480764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02480764, "Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02480764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*